Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410

1.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Jun 12. pii: S2352-3026(18)30051-6. doi: 10.1016/S2352-3026(18)30051-6. [Epub ahead of print] Review.

PMID:
29907552
2.

How and when I do allogeneic transplant in CLL.

Gribben JG.

Blood. 2018 Jul 5;132(1):31-39. doi: 10.1182/blood-2018-01-785998. Epub 2018 May 11. Review.

PMID:
29752258
4.

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.

Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S, Marfa S, Lea N, Best S, Gribben J, Fitzgibbon J, Cutillas PR.

Leukemia. 2018 Apr 7. doi: 10.1038/s41375-018-0032-1. [Epub ahead of print] No abstract available.

PMID:
29626197
5.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Mar 27:JCO2017763656. doi: 10.1200/JCO.2017.76.3656. [Epub ahead of print]

PMID:
29584548
6.

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S, Davies JK, Johnson P, Calaminici M, Montoto S, Auer R, Chelala C, Gribben JG, Graham TA, Fest T, Fitzgibbon J, Okosun J.

Leukemia. 2018 May;32(5):1258-1263. doi: 10.1038/s41375-018-0043-y. Epub 2018 Feb 8. No abstract available.

7.

Predictors of Reoperation and Failure to Rescue in Bariatric Surgery.

Gribben JL, Ilonzo N, Neifert S, Michael Leitman I.

JSLS. 2018 Jan-Mar;22(1). pii: e2017.00074. doi: 10.4293/JSLS.2017.00074.

8.

International practices in the dietary management of fructose 1-6 biphosphatase deficiency.

Pinto A, Alfadhel M, Akroyd R, Atik Altınok Y, Bernabei SM, Bernstein L, Bruni G, Caine G, Cameron E, Carruthers R, Cochrane B, Daly A, de Boer F, Delaunay S, Dianin A, Dixon M, Drogari E, Dubois S, Evans S, Gribben J, Gugelmo G, Heidenborg C, Hunjan I, Kok IL, Kumru B, Liguori A, Mayr D, Megdad E, Meyer U, Oliveira RB, Pal A, Pozzoli A, Pretese R, Rocha JC, Rosenbaum-Fabian S, Serrano-Nieto J, Sjoqvist E, Timmer C, White L, van den Hurk T, van Rijn M, Zweers H, Ziadlou M, MacDonald A.

Orphanet J Rare Dis. 2018 Jan 25;13(1):21. doi: 10.1186/s13023-018-0760-3.

9.

Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.

Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S, Öztürk S, Zenz T, Stilgenbauer S, Li-Weber M, Krammer PH, Gribben JG, Lichter P, Seiffert M.

Haematologica. 2018 Apr;103(4):688-697. doi: 10.3324/haematol.2017.177808. Epub 2018 Jan 11.

10.

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.

Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C, Stilgenbauer S.

Br J Haematol. 2018 Mar;180(5):666-679. doi: 10.1111/bjh.15080. Epub 2018 Jan 9.

PMID:
29318593
11.

Acute myeloid leukemia xenograft success prediction: Saving time.

Griessinger E, Vargaftig J, Horswell S, Taussig DC, Gribben J, Bonnet D.

Exp Hematol. 2018 Mar;59:66-71.e4. doi: 10.1016/j.exphem.2017.12.002. Epub 2017 Dec 15.

12.

Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, Montfort A, Dowe T, Gribben J, Jones JL, Kocher HM, Serody JS, Vincent BG, Connelly J, Brenton JD, Chelala C, Cutillas PR, Lockley M, Bessant C, Knight MM, Balkwill FR.

Cancer Discov. 2018 Mar;8(3):304-319. doi: 10.1158/2159-8290.CD-17-0284. Epub 2017 Dec 1.

PMID:
29196464
13.

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.

Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D.

Nat Commun. 2017 Nov 22;8(1):1679. doi: 10.1038/s41467-017-01834-4.

14.

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, Jones JL, Gribben JG, Jurkowski TP, Ficz G.

Nat Commun. 2017 Nov 13;8(1):1450. doi: 10.1038/s41467-017-01078-2.

15.

Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.

Davies JK, Hassan S, Sarker SJ, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG, Cavenagh JD.

Br J Haematol. 2018 Feb;180(3):346-355. doi: 10.1111/bjh.14980. Epub 2017 Oct 26.

PMID:
29076145
16.

Dietary practices in propionic acidemia: A European survey.

Daly A, Pinto A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei SM, Bollhalder S, Cassiman D, Champion H, Chan H, Dalmau J, de Boer F, de Laet C, de Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Kaalund Hansen K, Ter Horst NM, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs GE, Kok IL, Kowalik A, Laguerre C, Le Verge S, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Och U, Robert M, Rocha JC, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Skeath R, Stolen LH, Terry A, Timmer C, Tomlinson L, Tooke A, Vande Kerckhove K, van Dam E, van den Hurk T, van der Ploeg L, van Driessche M, van Rijn M, van Wegberg A, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White FJ, White L, Zweers H, MacDonald A.

Mol Genet Metab Rep. 2017 Oct 3;13:83-89. doi: 10.1016/j.ymgmr.2017.09.002. eCollection 2017 Dec.

17.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

PMID:
28985567
18.

Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia.

Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Montaner B, Chakravarty P, Bhaw L, Diana G, Lassailly F, Gribben J, Bonnet D.

Cancer Cell. 2017 Sep 11;32(3):324-341.e6. doi: 10.1016/j.ccell.2017.08.001. Epub 2017 Sep 1.

19.

Lamin B1 regulates somatic mutations and progression of B-cell malignancies.

Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A.

Leukemia. 2018 Feb;32(2):364-375. doi: 10.1038/leu.2017.255. Epub 2017 Aug 14.

20.

Restoring leukemia cell function from the inside out.

Gribben JG.

Blood. 2017 Jun 15;129(24):3137-3138. doi: 10.1182/blood-2017-04-776344. No abstract available.

21.

Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.

Edelmann J, Gribben JG.

J Oncol Pract. 2017 Jun;13(6):371-377. doi: 10.1200/JOP.2017.023291. Review.

PMID:
28605616
22.

The role of stem cell transplant for lymphoma in 2017.

Gribben JG.

Hematol Oncol. 2017 Jun;35 Suppl 1:25-29. doi: 10.1002/hon.2396. Review. No abstract available.

PMID:
28591422
23.

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, Haenel A, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.

Bone Marrow Transplant. 2017 Aug;52(8):1120-1125. doi: 10.1038/bmt.2017.88. Epub 2017 May 22.

PMID:
28530668
24.

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D.

Haematologica. 2017 Aug;102(8):1413-1423. doi: 10.3324/haematol.2017.165415. Epub 2017 Apr 14.

25.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

26.

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K, Gribben JG, Friedberg JW, Seymour JF, Cavalli F, Zucca E.

Hematol Oncol. 2017 Dec;35(4):397-407. doi: 10.1002/hon.2411. Epub 2017 Apr 4. Review.

PMID:
28378425
27.

Delayed Second Dose Antibiotics for Patients Admitted From the Emergency Department With Sepsis: Prevalence, Risk Factors, and Outcomes.

Leisman D, Huang V, Zhou Q, Gribben J, Bianculli A, Bernshteyn M, Ward MF, Schneider SM.

Crit Care Med. 2017 Jun;45(6):956-965. doi: 10.1097/CCM.0000000000002377.

PMID:
28328652
28.

Dietary practices in isovaleric acidemia: A European survey.

Pinto A, Daly A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S, Cassiman D, Champion H, Chan H, Dalmau J, de Boer F, de Laet C, de Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Kaalund-Hansen K, Horst N, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs GE, Kok IL, Kowalik A, Laguerre C, Le Verge S, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Robert M, Rocha JC, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Stolen LH, Terry A, Timmer C, Tomlinson L, Tooke A, Vande Kerckhove K, van Dam E, van den Hurk T, van der Ploeg L, van Driessche M, van Rijn M, van Teeffelen-Heithoff A, van Wegberg A, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White FJ, White L, Zweers H, MacDonald A.

Mol Genet Metab Rep. 2017 Feb 27;12:16-22. doi: 10.1016/j.ymgmr.2017.02.001. eCollection 2017 Sep.

29.

Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.

Lucas FM, Gribben JG.

Methods Mol Biol. 2017;1584:533-544. doi: 10.1007/978-1-4939-6881-7_33.

PMID:
28255724
30.

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M, Bloor A, Pettitt A, Fegan C, Blundell J, Gribben JG, Phillips D, Hillmen P.

Leukemia. 2017 Oct;31(10):2085-2093. doi: 10.1038/leu.2017.65. Epub 2017 Apr 20.

PMID:
28216660
31.

Chronic lymphocytic leukaemia.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K.

Nat Rev Dis Primers. 2017 Feb 9;3:17008. doi: 10.1038/nrdp.2017.8. No abstract available.

PMID:
28179635
32.

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).

Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ, Mei J, Golany N, Zhang J, Gribben JG.

Leukemia. 2017 May;31(5):1240-1243. doi: 10.1038/leu.2017.47. Epub 2017 Jan 31. No abstract available.

33.

Early sepsis bundle compliance for non-hypotensive patients with intermediate versus severe hyperlactemia.

Leisman DE, Zemmel D'Amore JA, Gribben JL, Ward MF, Masick KD, Bianculli AR, Bradburn KH, D'Angelo JK, Doerfler ME.

Am J Emerg Med. 2017 Jun;35(6):811-818. doi: 10.1016/j.ajem.2017.01.029. Epub 2017 Jan 15.

PMID:
28126452
34.

Chronic lymphocytic leukaemia.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K.

Nat Rev Dis Primers. 2017 Jan 19;3:16096. doi: 10.1038/nrdp.2016.96. Review.

35.

Versatile humanized niche model enables study of normal and malignant human hematopoiesis.

Abarrategi A, Foster K, Hamilton A, Mian SA, Passaro D, Gribben J, Mufti G, Bonnet D.

J Clin Invest. 2017 Feb 1;127(2):543-548. doi: 10.1172/JCI89364. Epub 2017 Jan 9.

36.

Bone Health in Classic Galactosemia: Systematic Review and Meta-Analysis.

van Erven B, Welling L, van Calcar SC, Doulgeraki A, Eyskens F, Gribben J, Treacy EP, Vos R, Waisbren SE, Rubio-Gozalbo ME, Bosch AM.

JIMD Rep. 2017;35:87-96. doi: 10.1007/8904_2016_28. Epub 2016 Dec 20.

37.

Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.

Dermit M, Casado P, Rajeeve V, Wilkes EH, Foxler DE, Campbell H, Critchlow S, Sharp TV, Gribben JG, Unwin R, Cutillas PR.

Oncogene. 2017 May 11;36(19):2762-2774. doi: 10.1038/onc.2016.435. Epub 2016 Dec 19.

38.

Survival Benefit and Cost Savings From Compliance With a Simplified 3-Hour Sepsis Bundle in a Series of Prospective, Multisite, Observational Cohorts.

Leisman DE, Doerfler ME, Ward MF, Masick KD, Wie BJ, Gribben JL, Hamilton E, Klein Z, Bianculli AR, Akerman MB, D'Angelo JK, D'Amore JA.

Crit Care Med. 2017 Mar;45(3):395-406. doi: 10.1097/CCM.0000000000002184.

PMID:
27941371
39.

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.

Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2. No abstract available.

40.

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.

Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E, Launonen A, Sehn LH.

Ann Hematol. 2017 Feb;96(2):253-259. doi: 10.1007/s00277-016-2878-5. Epub 2016 Nov 30.

41.

Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors.

Sarker SJ, Smith SK, Chowdhury K, Ganz PA, Zimmerman S, Gribben J, Korszun A.

Support Care Cancer. 2017 Mar;25(3):739-748. doi: 10.1007/s00520-016-3454-1. Epub 2016 Nov 8.

42.

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ.

Blood. 2016 Dec 22;128(25):2931-2940. doi: 10.1182/blood-2016-04-712562. Epub 2016 Nov 4.

43.

RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.

Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki ÖY, Platzer R, Pfajfer L, Bilic I, Ban SA, Willmann KL, Mukherjee M, Supper V, Hsu HT, Banerjee PP, Sinha P, McClanahan F, Zlabinger GJ, Pickl WF, Gribben JG, Stockinger H, Bennett KL, Huppa JB, Dupré L, Sanal Ö, Jäger U, Sixt M, Tezcan I, Orange JS, Boztug K.

Nat Immunol. 2016 Dec;17(12):1352-1360. doi: 10.1038/ni.3575. Epub 2016 Oct 24.

PMID:
27776107
44.

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.

Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK, Rothery S, Ruivo N, Foster K, Waibel M, Johnstone RW, Harrison SJ, Westerman DA, Quach H, Gribben J, Robinson MD, Purton LE, Bonnet D, Lo Celso C.

Nature. 2016 Oct 27;538(7626):518-522. doi: 10.1038/nature19801. Epub 2016 Oct 17.

45.

Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.

Riches JC, Gribben JG.

Curr Cancer Drug Targets. 2016;16(8):689-700. Review.

PMID:
27055579
46.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

48.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
49.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD.

Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.

PMID:
27345636
50.

Stem Cell Transplantation for Refractory Crohn Disease--Reply.

Hawkey CJ, Lindsay J, Gribben J.

JAMA. 2016 Jun 21;315(23):2620-1. doi: 10.1001/jama.2016.4033. No abstract available.

PMID:
27327809

Supplemental Content

Loading ...
Support Center